Revolution Medicines' Rasonque Approved for Pancreatic Cancer
The FDA has approved Rasonque, a new pancreatic cancer drug by Revolution Medicines, marking the first treatment to target a genetic cause of the disease. The approval follows a clinical trial showing improved survival in second-line patients.
The Food and Drug Administration on Wednesday approved a life-extending treatment for advanced pancreatic cancer - a medicine made by the biotech company Revolution Medicines that is the first to attack a genetic cause of the aggressive, highly lethal malignancy.
The drug, called daraxonrasib, will be sold under the brand name Rasonque. The FDA’s approval was supported by a practice-changing clinical trial that read out earlier this year. Patients with advanced pancreatic cancer who received Rasonque as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy.
“It will be transformative in the way we treat pancreas cancer. It’s the biggest development we’ve had in pancreas cancer in decades,” said Andrew Ko, a medical oncologist specializing in gastrointestinal cancers at the University of California, San Francisco. “I’m so thankful for this as an advance for our patients.”
FDA Approval of Rasonque
The FDA’s approval of Rasonque represents a significant shift in the treatment landscape for pancreatic cancer, which has long been associated with poor prognoses and limited therapeutic options. For the first time, a drug has been developed to directly target a genetic driver of the disease, offering hope for more effective interventions.
Clinical Trial Results
The pivotal trial supporting the approval enrolled patients with advanced pancreatic cancer who had already received first-line therapy. Those treated with Rasonque demonstrated a median overall survival of 13.2 months, more than double the 6.7 months observed in the control group receiving standard chemotherapy.
Expert Reaction
Andrew Ko, a medical oncologist at the University of California, San Francisco, described the approval as “the biggest development we’ve had in pancreas cancer in decades,” emphasizing its potential to transform patient outcomes.
Implications for Treatment
Rasonque’s mechanism of action targets a specific genetic alteration in pancreatic cancer cells, distinguishing it from conventional chemotherapy. The approval may pave the way for similar targeted therapies in other hard-to-treat cancers.
The source article is exclusive to STAT+ subscribers. Unlock this article - plus daily coverage and analysis of the biotech sector - by subscribing to STAT+.
